Vertex 770-115 An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 years of Age or Younger With Cystic Fibrosis

Grants and Contracts Details

StatusFinished
Effective start/end date11/25/1311/30/15

Funding

  • Vertex Pharmaceuticals Inc: $2,500.00